Syros Pharmaceuticals (NASDAQ:SYRS - Get Free Report) announced its earnings results on Tuesday. The company reported ($0.79) EPS for the quarter, beating analysts' consensus estimates of ($0.89) by $0.10, Zacks reports. Syros Pharmaceuticals had a negative net margin of 1,656.34% and a negative return on equity of 227.91%. During the same quarter in the previous year, the company earned ($0.85) earnings per share.
Syros Pharmaceuticals Price Performance
Shares of SYRS stock traded up $0.08 during mid-day trading on Wednesday, hitting $5.51. The company had a trading volume of 169,241 shares, compared to its average volume of 200,467. The company has a market capitalization of $147.28 million, a P/E ratio of -0.96 and a beta of 1.75. Syros Pharmaceuticals has a 52-week low of $2.09 and a 52-week high of $8.17. The company has a debt-to-equity ratio of 2.07, a current ratio of 3.95 and a quick ratio of 3.95. The stock's 50 day moving average price is $5.53 and its 200-day moving average price is $5.54.
Analyst Ratings Changes
A number of brokerages recently commented on SYRS. Piper Sandler reaffirmed an "overweight" rating and issued a $13.00 target price on shares of Syros Pharmaceuticals in a report on Wednesday, April 3rd. HC Wainwright reissued a "buy" rating and issued a $15.00 target price on shares of Syros Pharmaceuticals in a report on Wednesday. Finally, StockNews.com cut shares of Syros Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Wednesday, April 17th.
Read Our Latest Report on Syros Pharmaceuticals
About Syros Pharmaceuticals
(
Get Free Report)
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.
Read More
Before you consider Syros Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Syros Pharmaceuticals wasn't on the list.
While Syros Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.
Get This Free Report
